Current treatment options |
Diverse waaronder everolimus, palbociclib, letrozol, fulvestrant etc. |
Therapeutic value |
Possible added value |
Substantiation |
De SOLAR-1 studie laat een langere PFS zien ten opzichte van placebo. De overall response rate (ORR) in het PIK3CA-mutatie cohort was 26,6% in de alpelisib plus fulvestrant groep tegenover 12,8% in de placebo plus fulvestrant groep. Voor de totale studie populatie was de 'rate of grade ≥3 adverse events (AEs)' 76,1% in de alpelisib plus fulvestrant groep tegenover 35,5% in de placebo plus fulvestrant groep. |
Duration of treatment |
Average 8.2 month / months |
Frequency of administration |
1 times a day |
Dosage per administration |
300 mg |
References |
NCT02437318 (SOLAR-1); ESMO Abstract LBA3_PR |